SEC Form 4 · accession 0000850261-18-000047
Sorrento Therapeutics, Inc. · SRNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jerome B Zeldis
Officer — See Remarks
Period of report
Nov 26, 2018
Accepted (ET)
Nov 27, 2018 · 7:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000850261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $3.57 | Nov 26, 2018 | A | 100,000 | A | — | Nov 26, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F11/4th of the original number of shares subject to the option shall vest on November 26, 2019 and 1/48th of the original number of shares subject to the option shall vest following each one month period of service after November 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Remarks
Chief Medical Officer and President of Clinical Development